Lee, K. Et Al. 2016. PATIENT-REPORTED OUTCOME DATA FROM THE LUX-LUNG 8 PHASE III GLOBAL TRIAL OF AFATINIB VERSUS ERLOTINIB AS SECOND-LINE TREATMENT FOR ADVANCED SQUAMOUS CELL CARCINOMA OF THE LUNG FOLLOWING FIRST-LINE PLATINUM-BASED CHEMOTHERAPY.. ONCOLOGY NURSING FORUM , vol.43, no.2 .

Lee, K., GÖKER, E., COŞKUN, H. Ş., Gordon, J., & Gadgeel, S., (2016). PATIENT-REPORTED OUTCOME DATA FROM THE LUX-LUNG 8 PHASE III GLOBAL TRIAL OF AFATINIB VERSUS ERLOTINIB AS SECOND-LINE TREATMENT FOR ADVANCED SQUAMOUS CELL CARCINOMA OF THE LUNG FOLLOWING FIRST-LINE PLATINUM-BASED CHEMOTHERAPY.. ONCOLOGY NURSING FORUM , vol.43, no.2.

Lee, Karen Et Al. "PATIENT-REPORTED OUTCOME DATA FROM THE LUX-LUNG 8 PHASE III GLOBAL TRIAL OF AFATINIB VERSUS ERLOTINIB AS SECOND-LINE TREATMENT FOR ADVANCED SQUAMOUS CELL CARCINOMA OF THE LUNG FOLLOWING FIRST-LINE PLATINUM-BASED CHEMOTHERAPY.," ONCOLOGY NURSING FORUM , vol.43, no.2, 2016

Lee, Karen Et Al. "PATIENT-REPORTED OUTCOME DATA FROM THE LUX-LUNG 8 PHASE III GLOBAL TRIAL OF AFATINIB VERSUS ERLOTINIB AS SECOND-LINE TREATMENT FOR ADVANCED SQUAMOUS CELL CARCINOMA OF THE LUNG FOLLOWING FIRST-LINE PLATINUM-BASED CHEMOTHERAPY.." ONCOLOGY NURSING FORUM , vol.43, no.2, 2016

Lee, K. Et Al. (2016) . "PATIENT-REPORTED OUTCOME DATA FROM THE LUX-LUNG 8 PHASE III GLOBAL TRIAL OF AFATINIB VERSUS ERLOTINIB AS SECOND-LINE TREATMENT FOR ADVANCED SQUAMOUS CELL CARCINOMA OF THE LUNG FOLLOWING FIRST-LINE PLATINUM-BASED CHEMOTHERAPY.." ONCOLOGY NURSING FORUM , vol.43, no.2.

@article{article, author={Karen Lee Et Al. }, title={PATIENT-REPORTED OUTCOME DATA FROM THE LUX-LUNG 8 PHASE III GLOBAL TRIAL OF AFATINIB VERSUS ERLOTINIB AS SECOND-LINE TREATMENT FOR ADVANCED SQUAMOUS CELL CARCINOMA OF THE LUNG FOLLOWING FIRST-LINE PLATINUM-BASED CHEMOTHERAPY.}, journal={ONCOLOGY NURSING FORUM}, year=2016}